SWK Holdings Corp

SWK — Investor Presentation (May 2022)

35 slides from SWK's investor presentation, May 18, 2022

  1. Slide 1: Collaborative Approach to Life Science Financing

    1 Collaborative Approach to Life Science Financing Shareholder Presentation May 17, 2022

  2. Slide 2: Forward-looking and Cautionary Statements

    2 Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu

  3. Slide 3: SWK Holdings - Overview

    SWK Holdings - Overview 3 Underserved, High - Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial - stage healthcare companies and royalty owners • SWK targets $5mm to $25mm financings, a market niche that is largely ignored by

  4. Slide 4: SWK Holdings - Segments

    4 SWK Holdings - Segments LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Product acquisitions • Peptelligence ® and ProPerma Œ dosing technologies • CDMO and CMO services • 505b2 drug development SWK operates through two segments: Lif

  5. Slide 5: Life Science Finance Opportunity

    5 Life Science Finance Opportunity Achieve high current yield from investment in non - correlated assets Access to capital is challenging for small/mid - sized life science companies - Few participants exist for sub - $25mm life science financings Life science products are highly portable - Approved

  6. Slide 6: Value Creation Strategy

    6 Value Creation Strategy Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider for this underserved market • Majority of financings structured with warrants or other equity - like upside features to enhance return profile Select

  7. Slide 7: Book Value Components

    7 Book Value Components Tangible Finance Book Value / Share = $18.39 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill * , and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma Net Book Value / Share = $1.19 • In August 2

  8. Slide 8: Corporate Milestones

    8 Corporate Milestones 2014 x $113mm raised through private placement and rights offering x Ended year with $93mm yielding assets 2015 x Winston Black named CEO x 1/10 effective reverse stock split x Ended year with $99mm yielding assets 2016 x Team rebuilt and investment process improved x Ended ye

  9. Slide 9: First Quarter 2022 Recap

    First Quarter 2022 Recap 9 CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • During first quarter of 2022, completed two structured debt transactions deploying $18.5 million with an additional $4.2 million funded to existing borrowers • Received a $10.7 million cash payment from B&D Denta

  10. Slide 10: Finance Segment Portfolio Overview: 1Q22

    76% 22% 2% Portfolio Composition First Lien Royalty Warrants 10 Finance Segment Portfolio Overview: 1Q22 * Finance receivables and marketable investments; does not include new or repaid finance receivables closed post - quarter ** Includes public company warrants; private warrants carried at zero va

  11. Slide 11: Financial Snapshot

    $152.0 $167.1 $175.1 $205.9 $182.7 $189.4 $100 $125 $150 $175 $200 $225 2017 2018 2019 2020 2021 1Q22 Total Yielding Assets* ($ in millions; at end of period) $37.5 $26.0 $30.7 $36.7 $56.2 $57.9 $20 $25 $30 $35 $40 $45 $50 $55 $60 2017 2018 2019 2020 2021 LTM 1Q22 Total Revenue ($ in millions) $208.

  12. Slide 12: Financing Strategy: Effective Yield

    12.5% 13.0% 13.5% 14.0% 14.5% 15.0% $140.0 $160.0 $180.0 $200.0 $220.0 Yielding Portfolio and Weighted Effective Yield ($ in millions; at end of period) Yielding Portfolio* Effective Yield** 12 Financing Strategy SWK Targets Low - to - Mid Teens Effective Yields 1Q22 Finance Segment Effective Yield

  13. Slide 13: Financing Strategy: Realized Yield vs Effective Yield

    10.0% 12.5% 15.0% 17.5% 20.0% 22.5% 25.0% Realized Yield vs Effective Yield ($ in millions; at end of period) Effective Yield Realized Yield* 13 Financing Strategy SWK’s Portfolio Realized Yield Has Consistently Exceeded the Projected Yield as Actual Receipts Exceeded Internal Forecasts *Portfolio R

  14. Slide 14: Current Structured Credit Portfolio

    14 Current Structured Credit Portfolio Trio Healthcare 07.01.2021 $9.5 million – Structured Credit

  15. Slide 15: Current Royalty Portfolio

    15 Current Royalty Portfolio

  16. Slide 16: Portfolio Realizations

    16 Portfolio Realizations As of May 9, 2022 , SWK has exited 27 financings for a total 1.4x CoC return and 20% weighted average IRR ̶ 24 resulted in positive realizations with a cumulative 1.5x CoC and weighted average 27% IRR ̶ SynCardia position was sold to distressed private equity firm with SWK

  17. Slide 17: Portfolio Realizations to Strategic Buyers

    17 Portfolio Realizations to Strategic Buyers 13 realizations to strategic buyers demonstrated a median 28% LTV of SWK’s original loan value 9 of the 13 businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology $ in mm Target Buyer Closing Date

  18. Slide 18: Sourcing

    18 Sourcing SWK has a well - developed and diversified sourcing network SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $25mm financings From 2017

  19. Slide 19: Financing Structures

    Financing Structures 19 Product Acquisition • Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commer

  20. Slide 20: Value Proposition to Partners

    20 Value Proposition to Partners Smaller companies often don’t have financial profile to qualify for traditional financing sources Companies in this niche often have few options outside of a dilutive equity raise The IPO market is largely closed to companies of this size requiring expensive and diff

  21. Slide 21: Historical Financing: Narcan Royalty

    Historical Financing: Narcan Royalty 21 OPPORTUNITY SOLUTION • Opiant is a publicly - traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation • Novel formulation has a faster time to onset and more convenient and safer administration • Opiant ne

  22. Slide 22: Historical Financing: Galil Medical

    Historical Financing: Galil Medical 22 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In

  23. Slide 23: Enteris BioPharma Acquisition – A Transformational Opportunity

    Enteris BioPharma Acquisition – A Transformational Opportunity 23 • Natural extension to SWK’s existing royalty monetization business, which generates income via royalties on life science products in a mix of structures • Enteris offers opportunity to create wholly - owned portfolio of milestones an

  24. Slide 24: Enteris Corporate Overview

    24 Enteris Corporate Overview Commercial Platform Proven Technology, Late - Stage Commercial Partnerships, and Internal Pipeline Drug Delivery Technology Internal 505(b)(2) Pipeline Company Highlights • Peptelligence and ProPerma allow for oral delivery of drugs that are typically injected, includin

  25. Slide 25: Enteris: Cara Therapeutics and Oral KORSUVA

    Enteris: Cara Therapeutics and Oral KORSUVA Œ 25 Oral KORSUVA Licensing Agreement Milestone Payment • Formulated with Enteris’ Peptelligence technology • Currently the subject of four late - stage clinical trials for pruritus • Phase 2 trial targeting pruritus in patients with CKD produced positive

  26. Slide 26: Leadership Team

    26 Leadership Team Winston Black Chief Executive Officer • Appointed CEO in 2016 • Co - founded PBS Capital Management • Prior leadership positions at Highland Capital Management, Mallette Capital Management and ATX Communications Charles Jacobsen Chief Financial Officer • Appointed CFO in 2012 • Cu

  27. Slide 27: Growth Opportunity

    27 Growth Opportunity LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • SWK’s has generated portfolio returns amongst the highest in the peer group • Deal pipeline remains strong with 2022 originations anticipated to return to historical levels • SWK confident in continued B/V per share growth of >

  28. Slide 28: Why Invest in SWKH – Attractive Risk Reward Scenario

    Why Invest in SWKH – Attractive Risk Reward Scenario 28 Attractive Valuation • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility Strong Management/ Proven Pro

  29. Slide 29: Balance Sheet

    $ in 000s Mar-22 Dec-21 Dec-20 Dec-19 Dec-18 ASSETS Cash and cash equivalents 41,399$ 42,863$ 3,008$ 11,158$ 20,227$ Interest and accounts receivable, net 1,979 1,803 1,911 2,554 2,195 Marketable investments 1,006 1,034 1,210 1,802 - Other current assets 1,576 1,727 542 1,087 138 Total current asset

  30. Slide 30: Income Statement

    30 Income Statement $ in 000s, except per share amounts LTM 1Q22 Dec-21 Dec-20 Dec-19 Dec-18 Revenues Finance receivable interest income, including fees 41,046$ 39,310$ 30,800$ 30,117$ 25,978$ Pharmaceutical development 16,160 16,122 5,903 621 - Other 707 723 9 9 12 Total Revenues 57,913 56,155 36,7

  31. Slide 31: Cash Flow Statement

    31 Cash Flow Statement $ in 000s,* LTM 1Q22 Dec-21 Dec-20 Dec-19 Dec-18 Cash flows from operating activities: Consolidated net income $26,018 $25,929 $5,202 $23,828 $6,195 Adjustments to reconcile net income to net cash provided by operating activities: Provision for loan credit losses - - - 2,209 6

  32. Slide 32: Non-GAAP Net Income Reconciliation

    $ in 000s, except per share amounts LTM 1Q22 Dec-21 Dec-20 Dec-19 Dec-18 Consolidated net income (loss) 26,018$ 25,929$ 5,202$ 23,828$ 6,195$ Add: income tax expense (benefit) 7,230 7,082 (1,537) (6,986) 42 Add: Enteris intangibles amortization 2,385 3,489 11,735 4,816 - Add (subtract): loss (gain)

  33. Slide 33: Book Value Reconciliation

    $ in 000s, except per share amounts Mar-22 Mar-22 SWK Specialty Finance Book Value, net Enteris Book Value, net* Stockholders' Equity (Book Value) 270,799$ Intangible assets, net 9,467$ Less: Deferred tax asset, net 19,460 Goodwill 8,404 Tangible book value 251,339$ Property and equipment, net 5,991

  34. Slide 34: Contact Information

    34 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor • Winston Black: ̶ Phone: 972.687.7251 ̶ Email: [email protected] • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: [email protected] • Office address: ̶ 14755 Preston Road, Ste 105 Dallas

  35. Slide 35: Collaborative Approach to Life Science Financing

    35 Collaborative Approach to Life Science Financing

SWK Holdings — Investor Presentation (May 2022) on 6ix